Cargando…
Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review
Anti-VEGF (vascular endothelial growth factor) therapy with the monoclonal antibody bevacizumab can cause gastrointestinal (GI) perforations. In recent years it became apparent that GI perforations also occur during treatment with antiangiogenic tyrosine kinase inhibitors (TKIs). It is of clinical i...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Springer Netherlands
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102838/ https://www.ncbi.nlm.nih.gov/pubmed/21188500 http://dx.doi.org/10.1007/s10456-010-9197-6 |